Foster & Motley Inc. Invests $2 Million in Halozyme Therapeutics, Inc. $HALO

Foster & Motley Inc. purchased a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the second quarter, according to its most recent disclosure with the SEC. The firm purchased 25,501 shares of the biopharmaceutical company’s stock, valued at approximately $1,996,000.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Horizon Investment Services LLC acquired a new stake in Halozyme Therapeutics during the 2nd quarter valued at approximately $2,254,000. Mizuho Markets Americas LLC boosted its stake in shares of Halozyme Therapeutics by 270.8% during the 4th quarter. Mizuho Markets Americas LLC now owns 1,268,673 shares of the biopharmaceutical company’s stock valued at $85,382,000 after buying an additional 926,526 shares during the last quarter. Chase Investment Counsel Corp acquired a new stake in shares of Halozyme Therapeutics during the second quarter worth approximately $2,035,000. Northwestern Mutual Wealth Management Co. grew its position in shares of Halozyme Therapeutics by 19,326.4% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 85,476 shares of the biopharmaceutical company’s stock worth $5,753,000 after buying an additional 85,036 shares in the last quarter. Finally, Hussman Strategic Advisors Inc. increased its stake in shares of Halozyme Therapeutics by 66.7% in the fourth quarter. Hussman Strategic Advisors Inc. now owns 52,500 shares of the biopharmaceutical company’s stock worth $3,533,000 after buying an additional 21,000 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Up 1.8%

NASDAQ:HALO opened at $104.89 on Wednesday. The firm has a market capitalization of $11.91 billion, a PE ratio of 31.31, a price-to-earnings-growth ratio of 0.40 and a beta of 0.85. The stock has a 50 day moving average of $80.97 and a 200-day moving average of $73.02. Halozyme Therapeutics, Inc. has a 52 week low of $61.22 and a 52 week high of $105.11. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The business had revenue of $481.00 million for the quarter, compared to the consensus estimate of $402.28 million. During the same quarter last year, the business posted $1.54 EPS. The business’s revenue was up 47.7% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Analysts predict that Halozyme Therapeutics, Inc. will post 7.77 EPS for the current year.

Wall Street Analysts Forecast Growth

HALO has been the subject of several research analyst reports. Leerink Partners raised shares of Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $83.00 to $110.00 in a research report on Friday, August 7th. Citizens Jmp increased their price target on shares of Halozyme Therapeutics from $92.00 to $93.00 and gave the stock a “market outperform” rating in a research report on Friday, August 7th. Morgan Stanley lowered their price objective on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. Wall Street Zen raised Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. Finally, HC Wainwright upped their price target on Halozyme Therapeutics from $95.00 to $115.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Nine research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Halozyme Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $91.20.

Insider Activity

In other news, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $67.58, for a total transaction of $1,351,600.00. Following the completion of the transaction, the chief executive officer owned 767,780 shares in the company, valued at approximately $51,886,572.40. This represents a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of Halozyme Therapeutics stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $75.00, for a total transaction of $547,800.00. Following the completion of the sale, the director owned 14,462 shares in the company, valued at approximately $1,084,650. This represents a 33.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 44,103 shares of company stock valued at $3,142,896. 2.50% of the stock is currently owned by company insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.